iPierian Raises Money to Advance Tau Antibody and Form Spin-Off

iPierian, Inc. recently announced that it has secured $30 million in financing. A portion of the money will be used to continue to advance iPierian’s drug development pipeline, which includes their anti-Tau antibody that could be used in the treatment of tau-based diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). In addition, a portion of the financing will be used to support a spin-off called True North Therapeutics. True North is developing humanized antibodies that inhibit toxicity associated with the complement pathway, with a focus on “hematologic, renal and neurological therapeutic areas.” Hopefully ALS is on their list of target therapeutic areas. Stay tuned to the ALS Forum for continued updates about this developing story.

iPierian, Inc. recently announced that it has secured $30 million in financing. A portion of the money will be used to continue to advance iPierian’s drug development pipeline, which includes their anti-Tau antibody that could be used in the treatment of tau-based diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). In addition, a portion of the financing will be used to support a spin-off called True North Therapeutics. True North is developing humanized antibodies that inhibit toxicity associated with the complement pathway, with a focus on “hematologic, renal and neurological therapeutic areas.” Hopefully ALS is on their list of target therapeutic areas. Stay tuned to the ALS Forum for continued updates about this developing story.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail